Antiviral Therapy for HCV-Associated Cryoglobulinemic Glomerulonephritis: Case Report and Review of the Literature

被引:7
|
作者
Fabrizi, Fabrizio [1 ]
Fogazzi, Giovanni Battista [1 ]
Cresseri, Donata [1 ]
Passerini, Patrizia [1 ]
Martin, Paul [4 ]
Donato, Maria Francesca [2 ,3 ]
Rumi, Maria Grazia [2 ,3 ]
Messa, Piergiorgio [1 ]
机构
[1] Maggiore Hosp, Div Nephrol, IRCCS Fdn, IT-20122 Milan, Italy
[2] Maggiore Hosp, Div Gastroenterol, IT-20122 Milan, Italy
[3] Univ Milan, Sch Med, Milan, Italy
[4] Univ Miami, Sch Med, Div Nephrol, Miami, FL USA
来源
KIDNEY & BLOOD PRESSURE RESEARCH | 2012年 / 35卷 / 06期
关键词
Hepatitis C; Glomerulonephritis; Cryoglobulinemia; Interferon; Rituximab; HEPATITIS-C VIRUS; RANDOMIZED CONTROLLED-TRIAL; MIXED CRYOGLOBULINEMIA; RITUXIMAB TREATMENT; INTERFERON-ALPHA; INFECTION; RIBAVIRIN; MANIFESTATIONS; PEGINTERFERON; INVOLVEMENT;
D O I
10.1159/000345515
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
We describe the case of a 51-year-old woman with HCV-associated cryoglobulinemic glomerulonephritis (GN). She presented mild deterioration of kidney function, non-nephrotic proteinuria, and active urinary sediment. Kidney biopsy showed features of membranoproliferative changes with some sclerosis. Sustained viral response (SVR) was obtained by 6 months of antiviral therapy (peg-IFN-alpha 2a plus ribavirin). SVR was linked with improvement of kidney function and remission of proteinuria. Clinical and virological remission persists over a 25-month follow-up. This case report emphasizes efficacy and safety of antiviral treatment of HCV-associated glomerulonephritis - preliminary but encouraging results exist. We identified by systematic review of the literature 9 studies (156 unique patients); the pooled estimate of frequency of sustained virological response after IFN-based therapy was 0.49 (95% confidence interval, CI: 0.21, 0.77; p < 0.0005; random effects model). Heterogeneity was found (I-2 = 98.9%, p < 0.0001). Two possible regimens should be considered for the treatment of HCV-associated cryoglobulinemic GN according to the clinical presentation. Immunosuppressive therapy is recommended for HCV-related kidney disease having aggressive course, and recent evidence supports rituximab (RTX) use with a reduced exposure to corticosteroids. We identified six studies (66 unique patients) on RTX therapy for HCV-associated kidney disease; at the end of RTX therapy, the pooled estimate of the mean decrease in proteinuria was 1.4 g/24 h (95% CI: 0.75, 2.05, p < 0.001); The p test for heterogeneity gave a value of 0.94 (I-2 = 0). Several questions related to RTX use remain. HCV-induced GN is uncommon among CKD patients of developed countries, and this clearly hampers prospective controlled clinical trials aimed to evaluate efficacy and safety of antiviral or immunosuppressive therapy in this population. Copyright (C) 2013 S. Karger AG, Basel
引用
收藏
页码:687 / 693
页数:7
相关论文
共 50 条
  • [1] Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: a case-based review
    Obrisca, Bogdan
    Jurubita, Roxana
    Sorohan, Bogdan
    Iliescu, Laura
    Baston, Catalin
    Bobeica, Raluca
    Andronesi, Andreea
    Leca, Nicolae
    Ismail, Gener
    [J]. CLINICAL RHEUMATOLOGY, 2019, 38 (12) : 3677 - 3687
  • [2] Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: a case-based review
    Bogdan Obrișcă
    Roxana Jurubiță
    Bogdan Sorohan
    Laura Iliescu
    Cătălin Baston
    Raluca Bobeică
    Andreea Andronesi
    Nicolae Leca
    Gener Ismail
    [J]. Clinical Rheumatology, 2019, 38 : 3677 - 3687
  • [3] Remission of HCV-associated glomerulonephritis with pegylated IFN and ribavirin therapy after liver transplantation: case report and literature review
    Donato, Maria Francesca
    Fabrizi, Fabrizio
    Fogazzi, Giovanni Battista
    Cresseri, Donata
    Passerini, Patrizia
    Martin, Paul
    Messa, Piergiorgio
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2013, 36 (01): : 63 - 68
  • [4] HCV-ASSOCIATED CRYOGLOBULINEMIC VASCULITIS
    Vasiliev, V. I.
    Palshina, S. G.
    Logvinenko, O. A.
    Safonova, T. N.
    Rodionova, E. B.
    Varlamova, E. J.
    Nekrasova, T. P.
    Radenska-Lopovok, S. G.
    Probatova, N. A.
    Alexandrova, E. N.
    Nasonov, E. L.
    [J]. TERAPEVTICHESKII ARKHIV, 2012, 84 (05): : 35 - 42
  • [5] Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis
    Milovanova, S. Y.
    Lopatkina, T. N.
    Kozlovskaya, L. V.
    Krasnova, T. N.
    [J]. TERAPEVTICHESKII ARKHIV, 2007, 79 (06): : 69 - 72
  • [6] The Successful Treatment of a Case of HCV-associated Cryoglobulinemic Glomerulonephritis with Rituximab, Direct-acting Antiviral Agents, Plasmapheresis and Long-term Steroid Despite Serologically Persistent Cryoglobulinemia
    Muro, Koji
    Toda, Naohiro
    Yamamoto, Shinya
    Yanagita, Motoko
    [J]. INTERNAL MEDICINE, 2021, 60 (04) : 583 - 589
  • [7] Monoclonal Gammopathy of Renal Significance Presenting as Cryoglobulinemic Glomerulonephritis: A Case Report and Review of Literature
    Goli, R.
    Raju, Bhushan
    Uppin, M. S.
    [J]. INDIAN JOURNAL OF NEPHROLOGY, 2018, 28 (03) : 229 - 231
  • [8] HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al
    Saadoun, David
    Cacoub, Patrice
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (09) : E59 - E59
  • [9] Glomerulonephritis associated with tuberculosis: A case report and literature review
    Solak, Yalcin
    Gaipov, Abduzhappar
    Anil, Melih
    Atalay, Huseyin
    Ozbek, Orhan
    Turkmen, Kultigin
    Polat, Ilker
    Turk, Suleyman
    [J]. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2013, 29 (06): : 337 - 342
  • [10] Interferon therapy for HCV-associated glomerulonephritis: Meta-analysis of controlled trials
    Fabrizi, F.
    Bruchfeld, A.
    Mangano, S.
    Dixit, V.
    Messa, P.
    Martin, P.
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2007, 30 (03): : 212 - 219